Hanglok-Tech

Hanglok-Tech Co., Ltd. emerged from national-level research initiatives to become a specialized developer of surgical robot systems for interventional radiology. Located in the Guangdong-Macao In-Depth Cooperation Zone in Hengqin, Zhuhai, the company focuses on creating an AIoT surgical ecosystem that spans percutaneous, endovascular, and non-vascular luminal interventions.

Company Overview

Hanglok-Tech was established in March 2020, building upon research outcomes from several national projects including the 2018 National Major Scientific Research Instrument Development Project for multi-organ malignant tumor precision interventional radiotherapy surgical robots, the Ministry of Science and Technology Key Research and Development Project for cavity interventional surgical robots, and the 863 Project for cerebrovascular real-time intervention mobile surgical robot systems.

The company operates from the Hengqin Macao Youth Entrepreneurship Valley, benefiting from the policy support of the Guangdong-Macao cooperation framework. Hanglok-Tech has established strategic partnerships with Macau University of Science and Technology and collaborates with the Guangdong Provincial Institute of Intelligence Science and Technology.

Core Products

SGNIO - Percutaneous Intervention Robot

SGNIO represents Hanglok-Tech’s primary product for CT-guided percutaneous procedures. The system targets lung biopsy and tumor ablation applications, featuring multi-loop feedback control that collects diverse intraoperative data to generate precise control outcomes. The product received the Governor Cup Gold Award for its design innovation.

MULLER - Endovascular Intervention Robot

MULLER addresses the endovascular intervention segment, designed for procedures within blood vessels. This master-slave remote interventional surgical robot system builds on the company’s core competencies in real-time navigation and precision control.

BINARY - Non-Vascular Luminal Intervention System

BINARY focuses on lung cancer diagnosis through non-vascular luminal approaches, complementing the percutaneous and endovascular product lines to provide broad interventional solutions.

Technology & Innovation

Hanglok-Tech has developed the “Zhuqueyun” (朱雀云) specialized robot operating system, introducing distributed science into surgical robotics. The company’s technology portfolio includes:

• Multi-loop feedback puncture interventional surgical control systems
• Portable needle holder implantation with near-infrared optical navigation
• Real-time 3D needle positioning capabilities
• AI-powered surgical planning and guidance

The company holds over 170 patents and has published research in peer-reviewed journals, including a 2024 article in IEEE Transactions on Medical Imaging on “3D/2D Vessel Registration based on Monte Carlo Tree Search and Manifold Regularization.”

Market Presence

Based in the Greater Bay Area, Hanglok-Tech benefits from the region’s concentration of medical institutions and research capabilities. Two products have entered clinical trials as of 2022, representing the company’s progression toward commercialization. The team comprises over 50 engineers dedicated to advancing the product pipeline.

Key Milestones

• 2020: Company established in Hengqin; received ¥20M angel investment led by Zhuhai Gree Venture Capital
• 2021: Robotic systems debuted at CCI Annual Conference; signed industry-university-research cooperation agreement with Zhuhai
• 2022: Secured approximately ¥300M investment; two products entered clinical trials
• 2023: Published IEEE research; co-sponsored Robot-assisted Medical Imaging Workshop
• 2024: Received recognition in IEEE Transactions on Medical Imaging
• 2025: Won Gold Award at the first Guangdong-Hong Kong-Macao Greater Bay Area Entrepreneurship Competition

Frequently Asked Questions

What types of surgical robots does Hanglok-Tech develop?

Hanglok-Tech develops three main product lines: SGNIO for percutaneous interventions such as lung biopsies, MULLER for endovascular procedures, and BINARY for non-vascular luminal interventions focused on lung cancer diagnosis.

Where is Hanglok-Tech located?

The company is headquartered in the Hengqin Macao Youth Entrepreneurship Valley in Zhuhai, within the Guangdong-Macao In-Depth Cooperation Zone.

What is the regulatory status of Hanglok-Tech’s products?

As of the latest available information, two of Hanglok-Tech’s products have entered clinical trials in China. The products have not yet received NMPA approval.